Hetero Drugs
Hetero Drugs Limited, commonly referred to as Hetero, is a prominent player in the global pharmaceutical industry, headquartered in Hyderabad, India. Established in 1993, the company has made significant strides in the development and manufacturing of a diverse range of generic and branded medications, particularly in the areas of anti-retrovirals, oncology, and cardiovascular treatments. With a strong presence in over 120 countries, Hetero is recognised for its commitment to quality and affordability, making essential medicines accessible to patients worldwide. The company’s extensive portfolio includes over 200 products, distinguished by their rigorous quality standards and innovative formulations. Hetero's dedication to research and development has positioned it as a leader in the pharmaceutical sector, contributing to its reputation for excellence and reliability in healthcare solutions.
DitchCarbon Score
How does Hetero Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hetero Drugs's score of 21 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hetero Drugs's reported carbon emissions
In 2023, Hetero Drugs reported total carbon emissions of approximately 412,461,000 kg CO2e, with Scope 1 emissions at about 213,330,000 kg CO2e and Scope 2 emissions at around 199,131,000 kg CO2e. This marks a reduction from 2022, where total emissions were approximately 428,943,000 kg CO2e, with Scope 1 at about 229,812,000 kg CO2e and Scope 2 at 199,131,000 kg CO2e. Over the past few years, Hetero has demonstrated a commitment to reducing its carbon footprint, with total emissions decreasing from approximately 429,811,000 kg CO2e in 2021 and 402,399,000 kg CO2e in 2020. However, the company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. Hetero Drugs has focused on managing its Scope 1 and Scope 2 emissions, but currently does not report on Scope 3 emissions. The company continues to work towards enhancing its sustainability practices in line with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 222,286,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 117,362,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hetero Drugs is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
